At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
SPR001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3-Month Phase 2 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
In Brief
A Phase 2 clinical trial evaluating SPR001 for Congenital Adrenal Hyperplasia and 2 related conditions. Completed, enrolled 11 participants across 8 sites.
Detailed Summary
This is a Phase 2 study of SPR001 for the treatment of classic CAH that will provide 12 weeks of open-label treatment to eligible subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia, CAH - 21-Hydroxylase Deficiency
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
First PostedSep 2018
Primary CompletionJul 2019
Study CompletionAug 2019
TodayJul 2026
First PostedSep 27, 2018
Enrollment StartSep 6, 2018
Primary CompletionJul 8, 2019
Study CompletionAug 9, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.8 years ago
Interventions
SPR001drug
Open label SPR001